IGM Biosciences, Inc.

NasdaqGS:IGMS Stock Report

Market Cap: US$528.6m

IGM Biosciences Valuation

Is IGMS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IGMS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IGMS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IGMS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IGMS?

Key metric: As IGMS barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IGMS. This is calculated by dividing IGMS's market cap by their current book value.
What is IGMS's PB Ratio?
PB Ratio7.1x
BookUS$78.95m
Market CapUS$528.64m

Price to Book Ratio vs Peers

How does IGMS's PB Ratio compare to its peers?

The above table shows the PB ratio for IGMS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7.1x
TSHA Taysha Gene Therapies
6.7x-0.4%US$506.2m
ORTX Orchard Therapeutics
4.7x12.5%US$380.1m
PRQR ProQR Therapeutics
13.9x-3.3%US$373.6m
IMNM Immunome
3.2x19.9%US$612.9m
IGMS IGM Biosciences
7.1x3.0%US$528.6m

Price-To-Book vs Peers: IGMS is good value based on its Price-To-Book Ratio (7.1x) compared to the peer average (7.1x).

Price to Book Ratio vs Industry

How does IGMS's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
IGMS 7.1xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IGMS is expensive based on its Price-To-Book Ratio (7.1x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is IGMS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IGMS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio7.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IGMS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IGMS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.40
US$19.60
+108.5%
55.7%US$48.00US$9.00n/a10
Nov ’25US$16.22
US$19.40
+19.6%
55.6%US$48.00US$9.00n/a10
Oct ’25US$14.50
US$19.10
+31.7%
56.6%US$48.00US$9.00n/a10
Sep ’25US$10.19
US$21.90
+114.9%
46.7%US$48.00US$12.00n/a10
Aug ’25US$9.68
US$21.40
+121.1%
48.2%US$48.00US$11.00n/a10
Jul ’25US$6.79
US$21.40
+215.2%
48.2%US$48.00US$11.00n/a10
Jun ’25US$8.33
US$21.40
+156.9%
48.2%US$48.00US$11.00n/a10
May ’25US$9.48
US$21.60
+127.8%
47.3%US$48.00US$12.00n/a10
Apr ’25US$9.45
US$21.60
+128.6%
47.3%US$48.00US$12.00n/a10
Mar ’25US$12.65
US$20.60
+62.8%
54.5%US$48.00US$7.00n/a10
Feb ’25US$11.38
US$18.85
+65.6%
64.0%US$48.00US$7.00n/a10
Jan ’25US$8.31
US$18.70
+125.0%
65.1%US$48.00US$7.00n/a10
Dec ’24US$6.22
US$20.60
+231.5%
55.1%US$48.00US$8.00n/a10
Nov ’24US$4.20
US$22.60
+438.1%
43.5%US$48.00US$11.00US$16.2210
Oct ’24US$8.35
US$22.09
+164.6%
43.1%US$48.00US$11.00US$14.5011
Sep ’24US$6.97
US$22.09
+216.9%
43.1%US$48.00US$11.00US$10.1911
Aug ’24US$10.36
US$30.45
+194.0%
35.4%US$49.00US$17.00US$9.6811
Jul ’24US$9.23
US$30.45
+230.0%
35.4%US$49.00US$17.00US$6.7911
Jun ’24US$12.84
US$30.45
+137.2%
35.4%US$49.00US$17.00US$8.3311
May ’24US$11.65
US$32.64
+180.1%
31.7%US$50.00US$20.00US$9.4811
Apr ’24US$13.74
US$35.82
+160.7%
27.5%US$50.00US$20.00US$9.4511
Mar ’24US$20.98
US$39.27
+87.2%
27.8%US$58.00US$24.00US$12.6511
Feb ’24US$23.16
US$39.27
+69.6%
27.8%US$58.00US$24.00US$11.3811
Jan ’24US$17.01
US$39.09
+129.8%
28.6%US$58.00US$22.00US$8.3111
Dec ’23US$21.00
US$39.09
+86.1%
28.6%US$58.00US$22.00US$6.2211
Nov ’23US$18.90
US$41.00
+116.9%
30.4%US$61.00US$27.00US$4.2011

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

2.5%

1Y

15.9%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

3.0%

1Y

11.4%